Corazon (Corsee) D. Sanders is Director at Ultragenyx Pharmaceutical Inc. (RARE). They have made 8 open-market trades across 2 companies since 2023, most recently 2026-06-15.
CIK 0001796536
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
0 open-market purchases, against 8 sales. Too few scored purchases to measure a record yet.
| Ticker | Shares | Value |
|---|---|---|
| BGNE | 57,226 | $10.6M |
| RARE | 21,095 | $307K |
| ONC | 804 | $297K |
| Total | $11.2M |
Shares reported on the most recent Form 4, priced at the 2026-06-15 close.
Counted per filing, not per execution lot — a purchase filled in several tranches is one decision.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| RARE | SELL | 2026-06-15 | 2026-06-15 | $25.05 | $50K | +20.4% | +23.9% | -46.7% |
| ONC | SELL | 2026-05-22 | 2026-05-27 | $309.59 | $66K | -8.2% | -5.2% | +27.8% |
| ONC | SELL | 2025-11-26 | 2025-12-01 | $340.89 | $1.8M | -4.2% | -9.3% | -6.2% |
| ONC | SELL | 2025-09-05 | 2025-09-09 | $337.00 | $898K | +3.1% | +3.5% | +0.6% |
| RARE | SELL | 2025-06-20 | 2025-06-23 | $37.39 | $180K | +7.5% | -24.6% | -20.6% |
| RARE | SELL | 2024-07-02 | 2024-07-03 | $40.98 | $24K | +12.8% | +25.8% | +40.8% |
| RARE | SELL | 2024-06-10 | 2024-06-10 | $41.10 | $143K | -4.5% | +2.4% | +34.6% |
| RARE | SELL · 10b5-1 | 2023-06-30 | 2023-06-30 | $46.76 | $27K | -4.0% | -6.3% | -23.5% |
| BGNE | SELL · 10b5-1 | 2023-06-23 | 2023-06-27 | $182.47 | $193K | +8.4% | +17.9% | +7.2% |
| RARE | SELL | 2023-06-08 | 2023-06-09 | $51.65 | $153K | -0.5% | -14.8% | -20.6% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.